Bayer and Finnish innovator Delsitech have partnered to develop new drug delivery technology for ophthalmology. The Collaboration and Technology Licence Agreement will see the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s ophthalmology drugs.
“This partnership with Bayer is an exciting development for DelSiTech. It follows an already successful and long-lasting collaboration with Bayer in which our Silica Matrix technology has been evaluated,” said Dr. Lasse Leino, CEO of DelSiTech. “We are very pleased that Bayer has chosen DelSiTech as its technology partner for ophthalmology drug delivery. It illustrates the great potential of biodegradable silica material in demanding drug delivery applications.”
“Successful ocular drug delivery is one of the biggest challenges in developing novel drug therapies for ophthalmic diseases. This agreement will support our work on innovative treatment options for a range of different eye diseases,” said Professor Andreas Busch, member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Drug Discovery. “This partnership with DelSiTech underlines Bayer’s continued commitment to leverage collaborations on cutting edge science in ophthalmology with the aim to improve the quality of life for patients.”
Bayer will fund all development and commercialisation costs of the collaborative projects. DelSiTech will receive undisclosed milestone payments on successful completion of different development stages as well as milestone payments and royalties on commercialisation and sales, respectively.